Free Newsletter
TapImmune, Aeras team on TB vaccine
TapImmune has signed a deal with non-profit development group Aeras for preclinical work on a tuberculous vaccine. TapImmune's technology is designed to make vaccines more effective by boosting antigen presentation through the use of the Transporter of Antigen Processing (TAP). Financial terms of the deal were not disclosed. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: